Sysmex Corporation (TYO:6869)

Market Cap	859.58B -47.8%
Revenue (ttm)	500.01B -1.7%
Net Income	35.46B -33.9%
EPS	56.89 -33.9%
Shares Out	615.31M
PE Ratio	24.56
Forward PE	22.64
Dividend	40.00 (2.86%)
Ex-Dividend Date	Mar 30, 2026

Volume	5,842,200
Open	1,396.50
Previous Close	1,381.50
Day's Range	1,385.00 - 1,434.00
52-Week Range	1,246.00 - 2,563.50
Beta	0.65
Analysts	Buy
Price Target	1,726.00 (+23.55%)
Earnings Date	May 14, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In fiscal year 2026, Sysmex's revenue was 500.01 billion, a decrease of -1.70% compared to the previous year's 508.64 billion. Earnings were 35.46 billion, a decrease of -33.93%.